Valuation: Cello Health plc

Market Cap 179M 240M 214M 197M 335M 22.72B 342M 2.35B 947M 11.99B 901M 881M 37.87B P/E 2024
43.4x
P/E 2025 -109x
Enterprise Value 179M 240M 214M 197M 335M 22.72B 342M 2.35B 947M 11.99B 901M 882M 37.88B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 51 13/08/2020
Director/Board Member 47 15/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
30/03/20 Free 80,000 0.0752%
30/03/20 Free

Chief Operating Officer

265,000 0.2492%
30/03/20 Free

Chief Financial Officer

250,000 0.2351%

Financials

2024 2025
Net sales - -
Net income 4.12M 5.53M 4.94M 4.53M 7.73M 524M 7.89M 54.16M 21.83M 277M 20.77M 20.33M 874M -1.64M -2.2M -1.96M -1.8M -3.07M -208M -3.13M -21.48M -8.66M -110M -8.24M -8.06M -346M
Net Debt 1.34M 1.8M 1.61M 1.47M 2.51M 170M 2.56M 17.61M 7.1M 89.91M 6.75M 6.61M 284M 42K 56.36K 50.31K 46.17K 78.74K 5.34M 80.31K 551K 222K 2.82M 212K 207K 8.89M
Projected Income Statement - Annual - Cello Health plc
Logo Cello Health plc
Cello Health plc, formerly Cello Group plc, is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company provides a range of biotech, diagnostics, devices and other non-healthcare clients. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company's pharmaceutical and healthcare clients. The Cello Signal Division provides market research and direct communications services to the Company's consumer facing clients. The Company delivers its services from office networks in the United Kingdom, the United States and Singapore.
Employees
-
Sector
-